The NIHR Manchester Biomedical Research Centre (BRC) is the largest BRC in the North of England and the beating heart of translational research across Greater Manchester, transforming scientific breakthroughs into diagnostic tests and life-saving treatments for patients.
Awarded £28.5million (2017-2022), Manchester BRC brings together world-leading researchers based at The University of Manchester and three of the country’s foremost NHS Trusts, with a vision to drive health improvements and lasting change for all through creative, inclusive and proactive research that identifies and bridges gaps between new discoveries and individualised care.
Manchester BRC is driving forward pioneering research in the areas of cancer (prevention and early detection, advanced radiotherapy, precision medicine), inflammation (musculoskeletal disease, respiratory disease, dermatology), and regenerative medicine (hearing health). These research themes are underpinned by cross-cutting themes in biomarkers, informatics and data science, and a rapid translational incubator that brings together key infrastructure in Greater Manchester essential to clinical study design and delivery.
A research team led by Professor Kevin Munro, Manchester BRC Hearing Health Theme Lead, have highlighted the difficulties people face with impacted ear wax, as more and more people face the prospect of ear wax removal services being discontinued at their GP surgeries.
Speaking to Arthritis Digest magazine, Professor Anne Barton explains how a diagnosis of inflammatory arthritis is life changing, but is no longer a life sentence.
There are plently of opportunities for people to help shape our research plans.
Research is vital to help us understand more about a particular disease or condition and how to treat them.